[go: up one dir, main page]

GB202020502D0 - Antibody composistion for treatment of corona virus infection - Google Patents

Antibody composistion for treatment of corona virus infection

Info

Publication number
GB202020502D0
GB202020502D0 GBGB2020502.7A GB202020502A GB202020502D0 GB 202020502 D0 GB202020502 D0 GB 202020502D0 GB 202020502 A GB202020502 A GB 202020502A GB 202020502 D0 GB202020502 D0 GB 202020502D0
Authority
GB
United Kingdom
Prior art keywords
composistion
antibody
treatment
virus infection
corona virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2020502.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Priority to GBGB2020502.7A priority Critical patent/GB202020502D0/en
Publication of GB202020502D0 publication Critical patent/GB202020502D0/en
Priority to CA3198333A priority patent/CA3198333A1/en
Priority to PCT/EP2021/087602 priority patent/WO2022136685A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
GBGB2020502.7A 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection Ceased GB202020502D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2020502.7A GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection
CA3198333A CA3198333A1 (en) 2020-12-23 2021-12-23 Antibody compositions for treatment of corona virus infection
PCT/EP2021/087602 WO2022136685A1 (en) 2020-12-23 2021-12-23 Antibody compositions for treatment of corona virus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2020502.7A GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection

Publications (1)

Publication Number Publication Date
GB202020502D0 true GB202020502D0 (en) 2021-02-03

Family

ID=74221492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2020502.7A Ceased GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection

Country Status (3)

Country Link
CA (1) CA3198333A1 (en)
GB (1) GB202020502D0 (en)
WO (1) WO2022136685A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891097A (en) * 2021-09-16 2022-08-12 中国科学院微生物研究所 Alpaca source nano antibody and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202210573D0 (en) * 2022-07-19 2022-08-31 Autolus Ltd Antibodies against SARS-CoV-2 and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338791T3 (en) 1992-08-21 2010-05-12 Vrije Universiteit Brussel IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS.
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP2000515002A (en) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー Recognition molecules that specifically interact with the active site or cleft of the target molecule
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
CN1252264C (en) 1999-04-22 2006-04-19 荷兰联合利华有限公司 Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE60031441T2 (en) 1999-11-29 2007-08-30 Unilever N.V. IMMOBILIZATION OF PROTEINS WITH THE HELP OF A POLYPEPTIDE EGMENTS
DK1233987T3 (en) 1999-11-29 2009-09-28 Bac Ip B V Immobilized single-domain antigen-binding molecules
ES2324280T3 (en) 2000-03-14 2009-08-04 Unilever N.V. VARIABLE DOMAINS OF THE HEAVY ANTIBODY CHAIN AGAINST HUMAN DIETETIC LIPASSES AND THEIR USES.
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1360207B1 (en) 2000-12-13 2011-06-22 Bac Ip B.V. Protein arrays of camelid heavy-chain immunoglobulin variable domains
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Method of constructing camel antibody library
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
JP2005517674A (en) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー Novel immunoconjugates useful for tumor treatment
BRPI0316092B8 (en) 2002-11-08 2021-05-25 Ablynx Nv single domain antibodies directed against tumor necrosis factor alpha and uses for them
EP2316852B1 (en) 2002-11-08 2014-03-05 Ablynx N.V. Stabilized single domain antibodies
CN100439400C (en) 2003-01-10 2008-12-03 埃博灵克斯股份有限公司 Therapeutic polypeptides, homologs thereof, fragments thereof, and uses thereof for modulating platelet-mediated aggregation
ES2352697T3 (en) 2003-11-07 2011-02-22 Ablynx N.V. CAMELIDAE VHH SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND USES OF THE SAME.
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
JP2008528010A (en) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ Methods for creating variable domain sequences of heavy chain antibodies
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
LT2444424T (en) 2005-05-20 2018-10-25 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
BRPI0812298A2 (en) 2007-05-24 2016-05-24 Ablynx Nv amino acid sequence directed against rankl and polypeptides comprising the same for the treatment of bone disorders and diseases.
SG10201605048XA (en) 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2746738C2 (en) 2014-05-16 2021-04-20 Аблинкс Нв Improved variable domains of immunoglobulins
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CN112094343B (en) * 2020-09-25 2022-05-13 中国科学技术大学 Alpaca source nano antibody combined with SARS-CoV-2 RBD

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891097A (en) * 2021-09-16 2022-08-12 中国科学院微生物研究所 Alpaca source nano antibody and application thereof
CN114891097B (en) * 2021-09-16 2023-01-24 中国科学院微生物研究所 An alpaca-derived nanobody and its application

Also Published As

Publication number Publication date
CA3198333A1 (en) 2022-06-30
WO2022136685A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
SI4204421T1 (en) Compounds and methods for treatment of viral infections
IL315102A (en) Compounds and methods for treatment of viral infections
CA3257287A1 (en) Methods for treatment of viral infections including sars-cov-2
PL4157272T3 (en) Remdesivir for the treatment of viral infections
IL287423A (en) Antibodies and methods for treatment of influenza a infection
EP3773632A4 (en) METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS
GB202020502D0 (en) Antibody composistion for treatment of corona virus infection
IL308478A (en) Methods and compositions for treatment of viral infection
IL281447A (en) Methods and compounds for the treatment of viral infections
GB2595513B (en) Treatment of infections
ZA202212662B (en) Use of compounds for treating viral infections
EP4351546A4 (en) HOST-DIRECTED DRUG COMBINATIONS FOR THE TREATMENT OF VIRUS INFECTIONS
EP4190800A4 (en) Peptide for treatment of corona virus infection disease covid-19 and use thereof
EP4153302C0 (en) TREATMENT OF VIRAL RESPIRATORY INFECTIONS
EP4025212B8 (en) Isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection
EP4203965A4 (en) Compounds and methods for prevention and treatment of virus infections
EP4146227A4 (en) TREATMENT OF VIRUS INFECTIONS
GB202117798D0 (en) Antibodies for the prevention and treatment of corona virus caused diseases
HK40088047A (en) Inhibitors of c5a for the treatment of corona virus infection
AU2020901054A0 (en) Methods for treatment of virus infections
EP4322967A4 (en) Treatment of virus infections
GB202312669D0 (en) Treatment of viral infections
HK40115603A (en) Compounds and methods for treatment of viral infections
GB202006160D0 (en) Treatment of viral infections
GB202004998D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)